514 related articles for article (PubMed ID: 38167329)
1. Programmable synthetic receptors: the next-generation of cell and gene therapies.
Teng F; Cui T; Zhou L; Gao Q; Zhou Q; Li W
Signal Transduct Target Ther; 2024 Jan; 9(1):7. PubMed ID: 38167329
[TBL] [Abstract][Full Text] [Related]
2. Modular design of synthetic receptors for programmed gene regulation in cell therapies.
Zhu I; Liu R; Garcia JM; Hyrenius-Wittsten A; Piraner DI; Alavi J; Israni DV; Liu B; Khalil AS; Roybal KT
Cell; 2022 Apr; 185(8):1431-1443.e16. PubMed ID: 35427499
[TBL] [Abstract][Full Text] [Related]
3. Engineering T Cells with Customized Therapeutic Response Programs Using Synthetic Notch Receptors.
Roybal KT; Williams JZ; Morsut L; Rupp LJ; Kolinko I; Choe JH; Walker WJ; McNally KA; Lim WA
Cell; 2016 Oct; 167(2):419-432.e16. PubMed ID: 27693353
[TBL] [Abstract][Full Text] [Related]
4. Post-translational covalent assembly of CAR and synNotch receptors for programmable antigen targeting.
Ruffo E; Butchy AA; Tivon Y; So V; Kvorjak M; Parikh A; Adams EL; Miskov-Zivanov N; Finn OJ; Deiters A; Lohmueller J
Nat Commun; 2023 May; 14(1):2463. PubMed ID: 37160880
[TBL] [Abstract][Full Text] [Related]
5. Engineering Programmable Material-To-Cell Pathways Via Synthetic Notch Receptors To Spatially Control Cellular Phenotypes In Multi-Cellular Constructs.
Garibyan M; Hoffman T; Makaske T; Do S; March AR; Cho N; Pedroncelli N; Lima RE; Soto J; Jackson B; Khademhosseini A; Li S; McCain M; Morsut L
bioRxiv; 2023 May; ():. PubMed ID: 37293089
[TBL] [Abstract][Full Text] [Related]
6. Tuning CARs: recent advances in modulating chimeric antigen receptor (CAR) T cell activity for improved safety, efficacy, and flexibility.
Celichowski P; Turi M; Charvátová S; Radhakrishnan D; Feizi N; Chyra Z; Šimíček M; Jelínek T; Bago JR; Hájek R; Hrdinka M
J Transl Med; 2023 Mar; 21(1):197. PubMed ID: 36922828
[TBL] [Abstract][Full Text] [Related]
7. Engineering of an enhanced synthetic Notch receptor by reducing ligand-independent activation.
Yang ZJ; Yu ZY; Cai YM; Du RR; Cai L
Commun Biol; 2020 Mar; 3(1):116. PubMed ID: 32170210
[TBL] [Abstract][Full Text] [Related]
8. Engineering Axl specific CAR and SynNotch receptor for cancer therapy.
Cho JH; Okuma A; Al-Rubaye D; Intisar E; Junghans RP; Wong WW
Sci Rep; 2018 Mar; 8(1):3846. PubMed ID: 29497107
[TBL] [Abstract][Full Text] [Related]
9. Strategies to Enhance the Therapeutic Efficacy, Applicability, and Safety of Genetically Engineered Immune Cells.
de Lima SCG; Fantacini DMC; Batista LC; Silveira RM; Furtado IP; Rossetti R; Brand H; Covas DT; de Souza LEB
Crit Rev Immunol; 2021; 41(1):41-67. PubMed ID: 33822524
[TBL] [Abstract][Full Text] [Related]
10. A synthetic notch (synNotch) system linking intratumoral immune-cancer cell communication to a synthetic blood biomarker assay.
Fu Y; Wang T; Ronald JA
Front Pharmacol; 2023; 14():1304194. PubMed ID: 38143496
[No Abstract] [Full Text] [Related]
11. Molecular Design, Optimization, and Genomic Integration of Chimeric B Cell Receptors in Murine B Cells.
Pesch T; Bonati L; Kelton W; Parola C; Ehling RA; Csepregi L; Kitamura D; Reddy ST
Front Immunol; 2019; 10():2630. PubMed ID: 31798579
[TBL] [Abstract][Full Text] [Related]
12. Synthetic Gene Circuits for Regulation of Next-Generation Cell-Based Therapeutics.
Teixeira AP; Fussenegger M
Adv Sci (Weinh); 2024 Feb; 11(8):e2309088. PubMed ID: 38126677
[TBL] [Abstract][Full Text] [Related]
13. Engineered CAR-Macrophages as Adoptive Immunotherapies for Solid Tumors.
Sloas C; Gill S; Klichinsky M
Front Immunol; 2021; 12():783305. PubMed ID: 34899748
[TBL] [Abstract][Full Text] [Related]
14. Instructional materials that control cellular activity through synthetic Notch receptors.
Lee JC; Brien HJ; Walton BL; Eidman ZM; Toda S; Lim WA; Brunger JM
Biomaterials; 2023 Jun; 297():122099. PubMed ID: 37023529
[TBL] [Abstract][Full Text] [Related]
15. Synthetic Biology in the Engineering of CAR-T and CAR-NK Cell Therapies: Facts and Hopes.
Clubb JD; Gao TA; Chen YY
Clin Cancer Res; 2023 Apr; 29(8):1390-1402. PubMed ID: 36454122
[TBL] [Abstract][Full Text] [Related]
16. Programming gene and engineered-cell therapies with synthetic biology.
Kitada T; DiAndreth B; Teague B; Weiss R
Science; 2018 Feb; 359(6376):. PubMed ID: 29439214
[TBL] [Abstract][Full Text] [Related]
17. Chimeric non-antigen receptors in T cell-based cancer therapy.
Guo J; Kent A; Davila E
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34344725
[TBL] [Abstract][Full Text] [Related]
18. Engineering a modular double-transmembrane synthetic receptor system for customizing cellular programs.
Zhou J; Ge Q; Wang D; Guo Q; Tao Y
Cell Rep; 2023 Apr; 42(4):112385. PubMed ID: 37043348
[TBL] [Abstract][Full Text] [Related]
19. Engineering CAR-T Cells for Next-Generation Cancer Therapy.
Hong M; Clubb JD; Chen YY
Cancer Cell; 2020 Oct; 38(4):473-488. PubMed ID: 32735779
[TBL] [Abstract][Full Text] [Related]
20. Getting better mileage with logically primed CARs.
Chen LC; Hou AJ; Chen YY
Med; 2021 Jul; 2(7):785-787. PubMed ID: 35590214
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
